Standard BioTools Q3 revenue falls

Standard BioTools

04/11/2025 22:02

Overview

Standard BioTools Q3 2025 revenue falls 11% yr/yr, reflecting declines in consumables and services

Adjusted EBITDA for Q3 2025 missed analyst expectations

Company implemented restructuring plan for $40 mln annualized cost savings

Outlook

Company expects positive adjusted EBITDA in 2026

Standard BioTools anticipates $550 mln cash from Illumina transaction in 2026

Company maintains 2025 revenue guidance of $165 mln to $175 mln

Result Drivers

RESTRUCTURING PLAN - Co implemented restructuring plan for $40 mln annualized cost savings, including 20% workforce reduction

CONSUMABLES REVENUE DECLINE - Decline in consumables revenue due to reduced project funding in flow and microfluidics, partially offset by imaging growth

SERVICES REVENUE DECREASE - Services revenue decreased due to fewer active service contracts and improved instrument quality, reducing on-demand revenue

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$19.60 mln
Q3 EPS
-$0.09
Q3 Net Income
-$34.68 mln
Q3 Adjusted EBITDA
Miss
-$16.50 mln
-$11.10 mln (3 Analysts)
Q3 Gross Margin
48.50%
Q3 Adjusted Gross Margin
53.50%
Q3 Operating Income
-$32.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Standard BioTools Inc is $1.78, about 30.1% above its November 3 closing price of $1.24

Press Release: ID:nGNX4FBLVf

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)